Zhizhong Ye

Prof. Dr. Zhizhong Ye


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
MHMunnaf Hossen
Munnaf Hossen
YMYanmei Ma
Yanmei Ma
ZYZhihua Yin
Zhihua Yin
YXYuhao Xia
Yuhao Xia
JDJing Du
Jing Du
ZHzhong huang
zhong huang
Autoimmune diseases (ADs) are characterized by the production of autoreactive lymphocytes, immune responses to self-antigens, and inflammation in related tissues and organs. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is majorly expressed in activated T cells and works as a critical regulator in the inflammatory response. In this review, we first describe the structure, expression, and how the signaling pathways of CTLA-4 participate in reducing effector T-cell activity and enhancing the immunomodulatory ability of regulatory T (Treg) cells to reduce immune response, maintain immune homeostasis, and maintain autoimmune silence. We then focused on the correlation between CTLA-4 and different ADs and how this molecule regulates the immune activity of the diseases and inhibits the onset, progression, and pathology of various ADs. Finally, we summarized the current progress of CTLA-4 as a therapeutic target for various ADs.

20 February 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
HZHuiqiong Zeng
Huiqiong Zeng
BLBaiwei Luo
Baiwei Luo
YZYue Zhang
Yue Zhang
ZXZhongyu Xie
Zhongyu Xie
ZYZhizhong Ye
Zhizhong Ye
The pathogenesis of reactive arthritis (ReA) has not been fully elucidated. In recent years, many researchers have confirmed that multiple cytokines are involved in the occurrence and development of ReA. Although ReA is self-limiting, it is still incurable for some patients who have no or a weak response to traditional drugs, such as non-steroidal anti-inflammatory agents, glucocorticoids and immunosuppressive agents. This is called refractory reactive arthritis. Currently, there is insufficient evidences for the treatment of refractory ReA with biological agents, though biological agents against cytokines have been developed over the past few years. This review summarizes the current development of clinical treatments of ReA with biological agents, which provides future investigations on refractory ReA with more evidence and references.

7 June 2022 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
HZHuiqiong Zeng
Huiqiong Zeng
KZKaixia Zhou
Kaixia Zhou
ZYZhizhong Ye
Zhizhong Ye
Autoimmune diseases (AIDs) are characterized by dysfunction and tissue destruction, and recent studies have shown that interleukin (IL)‑37 expression is dysregulated in AIDs. Among cytokines of the IL‑1 family, most are pro‑inflammatory agents, and as an anti‑inflammatory cytokine, IL‑37 may have the potential to alleviate excessive inflammation and can be used as a ligand or transcription factor that is involved in regulating innate and adaptive immunity. IL‑37 plays important roles in the development of AIDs. This review summarizes the biological characteristics and functions of IL‑37 and discusses the potential of IL‑37 as a therapeutic target for effective cytokine therapy and as a biomarker in AIDs.

1 July 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
YMYanmei Ma
Yanmei Ma
ZYZhihua Yin
Zhihua Yin
BCBingni Chen
Bingni Chen
HDHanying Dai
Hanying Dai
DWDandan Wu
Dandan Wu
ZHzhong huang
zhong huang

15 June 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ZYZhihua Yin
Zhihua Yin
HLHui-Ying Low
Hui-Ying Low
BCBrian Shiian Chen
Brian Shiian Chen
KHKuo-Shu Huang
Kuo-Shu Huang
YZYue Zhang
Yue Zhang
CHENGCHUNG WEICHENGCHUNG WEI
CHENGCHUNG WEI
Objectives: Previous research has shown a possible relationship between endometriosis and autoimmune diseases. However, the relationship between endometriosis and ankylosing spondylitis (AS) is lacking. Therefore, we intended to find possible associations between endometriosis and AS using ICD-9 coding data in a population-based retrospective cohort study in Taiwan.Method: Data for this retrospective cohort study were collected from the Taiwan National Health Insurance Research Database (NHIRD) between 2000–2012. We collected 13,145 patients with endometriosis and a 78,870 non-endometriosis comparison cohort. Diagnoses of endometriosis and AS were defined by the International Classification of Diseases-9 (ICD-9-CM) code for at least 3 outpatients or 1 hospitalization. Propensity score matching by comorbidities, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) usage were done for baseline comparability. Cox proportional hazard models were used to evaluate crude and adjusted hazard ratios.Results: The cumulative incidence of AS was higher in patients with endometriosis compared to the non-endometriosis comparison cohort (log-rank test, p = 0.015). The adjusted hazard ratio (aHR) of incidental AS in patients with endometriosis was 1.61 (95% CI = 1.11 to 2.35) in comparison to the non-endometriosis comparison cohort. An increased risk of AS was also observed in subjects with major depressive disorder (aHR = 5.05, 95% CI = 1.85 to 13.78). Stratified analyses of age subgroups showed consistent results. NSAID users had a lower risk of AS than NSAID non-users (aHR 4.57 vs 1.35, p for interaction = 0.031).Conclusions: In this retrospective population-based cohort study, we found a higher risk of AS in patients with endometriosis. We suggest that clinicians should pay attention to the occurrence of AS in patients with endometriosis.

1 June 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
YJYuning Jia
Yuning Jia
SAShoaib Anwaar
Shoaib Anwaar
LLLinyun Li
Linyun Li
ZYZhihua Yin
Zhihua Yin
ZYZhizhong Ye
Zhizhong Ye
ZHzhong huang
zhong huang